Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Haleon Plc (HLN)

Haleon Plc (HLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,164,480
  • Shares Outstanding, K 4,453,304
  • Annual Sales, $ 14,355 M
  • Annual Income, $ 1,843 M
  • EBIT $ 1,748 M
  • EBITDA $ 3,233 M
  • 60-Month Beta 0.19
  • Price/Sales 3.37
  • Price/Cash Flow 21.82
  • Price/Book 2.29

Options Overview Details

View History
  • Implied Volatility 55.08% (+2.40%)
  • Historical Volatility 19.78%
  • IV Percentile 94%
  • IV Rank 41.00%
  • IV High 104.85% on 11/20/25
  • IV Low 20.49% on 07/14/25
  • Expected Move (DTE 9) 1.29 (11.58%)
  • Put/Call Vol Ratio 1.67
  • Today's Volume 80
  • Volume Avg (30-Day) 77
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 3,038
  • Open Int (30-Day) 2,550
  • Expected Range 9.87 to 12.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.05
  • Growth Rate Est. (year over year) +1,997,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.71 +14.93%
on 01/15/26
11.20 -0.36%
on 02/11/26
+1.25 (+12.61%)
since 01/09/26
3-Month
9.30 +20.00%
on 12/09/25
11.20 -0.36%
on 02/11/26
+1.31 (+13.30%)
since 11/11/25
52-Week
8.71 +28.13%
on 09/25/25
11.42 -2.28%
on 06/02/25
+1.31 (+13.30%)
since 02/11/25

Most Recent Stories

More News
New Sensodyne Clinical Repair Toothpaste Launches with Breakthrough Formula for Rapid, Clinically Proven Sensitivity Relief

The breakthrough formula starts to repair sensitive areas of teeth after 60 seconds for substantial sensitivity relief in 3 days, delivering long-lasting relief with twice-daily brushing ...

HLN : 11.16 (+1.09%)
TUMS Unveils Sweepstakes and Limited-Edition Burn Ball to Help Fans "Pass the TUMS" Ahead of Football's Big Game

Viral mega-creator Airrack joins the brand for a playful campaign featuring trick shots, social sweepstakes and heartburn relief that's passable

HLN : 11.16 (+1.09%)
Glasgow Caledonian University to Lead £2.6m UK Doctoral Training Programme to Tackle Global Oral Health Challenges

Glasgow Caledonian University has secured £2.6 million to lead a major new UK-wide doctoral training programme to spearhead research into oral health and dental disease prevention. This...

HLN.LN : 406.300 (+1.47%)
HLN : 11.16 (+1.09%)
Haleon Recognized by Fast Company as a 2025 Brands That Matter Honoree

Haleon earns distinction in the Family of Brands category for building enduring trust and consumer connection Award highlights Haleon’s leadership in purposeful innovation and consumer...

HLN : 11.16 (+1.09%)
Haleon PLC (HLN) Gets a Hold from Barclays

Barclays analyst Warren Ackerman maintained a Hold rating on Haleon PLC on October 10 and set a price target of £3.80. The company’s shares closed last Friday at p338.50.Elevate Your Investing Strategy:...

HLN : 11.16 (+1.09%)
Goldman Sachs Sticks to Their Buy Rating for Haleon PLC (HLN)

In a report released on October 8, Olivier Nicolai from Goldman Sachs reiterated a Buy rating on Haleon PLC, with a price target of p440.00. The company’s shares closed last Friday at p338.50.Elevate...

HLN : 11.16 (+1.09%)
Morgan Stanley Keeps Their Buy Rating on Haleon PLC (HLN)

In a report released yesterday, Rashad Kawan from Morgan Stanley maintained a Buy rating on Haleon PLC, with a price target of £4.00. The company’s shares closed today at p338.50.Elevate Your Investing...

HLN : 11.16 (+1.09%)
Berenberg Bank Keeps Their Buy Rating on Haleon PLC (HLN)

Berenberg Bank analyst Bethan Davies maintained a Buy rating on Haleon PLC yesterday and set a price target of p507.00. The company’s shares closed yesterday at p339.80.Elevate Your Investing Strategy:...

HLN : 11.16 (+1.09%)
Haleon PLC Sponsored ADR (HLN) Gets a Buy from Berenberg Bank

Berenberg Bank analyst maintained a Buy rating on Haleon PLC Sponsored ADR yesterday and set a price target of $13.60. The company’s shares closed yesterday at $9.02.Elevate Your Investing Strategy:...

HLN : 11.16 (+1.09%)
Haleon Selects Salesforce Agentforce Life Sciences Cloud for Customer Engagement to Improve Engagement with Pharmacies and Healthcare Professionals with AI

Haleon plc (LSE/NYSE:HLN), a leading global consumer company that specialises in everyday health and Salesforce (NYSE:CRM), the world’s #1 AI CRM, today announced that Haleon will leverage Salesforce...

HLN.LN : 406.300 (+1.47%)
HLN : 11.16 (+1.09%)
CRM : 185.00 (-4.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Haleon plc engages in the research and development, manufacture and sale of various consumer healthcare products principally in North America, Europe, the Middle East, Africa, Latin America and the Asia Pacific. It provides therapeutic oral health, pain relief, respiratory health, digestive health and...

See More

Key Turning Points

3rd Resistance Point 11.40
2nd Resistance Point 11.30
1st Resistance Point 11.23
Last Price 11.16
1st Support Level 11.06
2nd Support Level 10.96
3rd Support Level 10.89

See More

52-Week High 11.42
Last Price 11.16
Fibonacci 61.8% 10.38
Fibonacci 50% 10.07
Fibonacci 38.2% 9.75
52-Week Low 8.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar